Abstract
A novel coronavirus (SARS-CoV-2) has recently emerged as a global threat. As the epidemic progresses, many disease modelers have focused on estimating the basic reproductive number ℛ0– the average number of secondary cases caused by a primary case in an otherwise susceptible population. The modeling approaches and resulting estimates of ℛ0 vary widely, despite relying on similar data sources. Here, we present a novel statistical framework for comparing and combining different estimates of ℛ0 across a wide range of models by decomposing the basic reproductive number into three key quantities: the exponential growth rate r, the mean generation interval 
, and the generation-interval dispersion κ. We then apply our framework to early estimates of ℛ0 for the SARS-CoV-2 outbreak. We show that many early ℛ0 estimates are overly confident. Our results emphasize the importance of propagating uncertainties in all components of ℛ0, including the shape of the generation-interval distribution, in efforts to estimate ℛ0 at the outset of an epidemic.
- SARS-CoV-2
- COVID-19
- novel coronavirus
- basic reproductive number
- generation interval
- Bayesian multilevel model
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BMB and DJDE were supported by Natural Sciences and Engineering Research Council (NSERC). ML was supported by Canadian Institutes of Health Research (CIHR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
R code is available in GitHub (https://github.com/parksw3/nCoV_framework).
